Stifel Upgrades Biogen to Buy, Announces $299 Price Target
Stifel analyst Paul Matteis upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $299 price target.
Need A Lyft For Your Portfolio? This Analyst Says Rideshare Stock Could Double As It Chases Down Uber
Analysts have highlighted a buying opportunity in shares of Lyft Inc (NASDAQ: LYFT) driven by multiple catalysts paired with overly negative sentiment, creating a favorable risk-reward setup.
Getty’s Valuation, Long-Term Fundamentals To Drive Value, Analyst Says
Benchmark analyst Mark Zgutowicz upgraded Getty Images Holdings, Inc (NYSE:GETY) to Buy from Hold with a $9 price target. He saw an…
DocuSign For Sale? Buyers May Target eSignature Company As Stock Declines
DocuSign Inc.’s (NASDAQ: DOCU) stock has limited downside as the negative catalysts have already played out, according to Wedbush.
The Analyst: Daniel Ives upgraded the rating for DocuSign from Underperform to Neutral, while maintaining the price target at $55.
Norwegian Cruise Now A Buy, But An Analyst Actually Prefers A Different Cruise Line
Norwegian Cruise Line Holdings Ltd’s (NYSE: NCLH) third-quarter preview shows a significant improvement in bookings, indicating that the company&r
Fortive Will Perform Consistently Even As Macro Slows Into 2023: Analyst
Fortive Corp’s (NYSE: FTV) stock valuation is “undemanding,” while the company faces lower macro risk to earnings, according to Morga
Deutsche Bank Upgrades CME Group to Buy
Deutsche Bank analyst Brian Bedell upgrades CME Group (NASDAQ:CME) from Hold to Buy.
Morgan Stanley Upgrades Fortive to Overweight, Announces $73 Price Target
Morgan Stanley analyst Joshua Pokrzywinski upgrades Fortive (NYSE:FTV) from Equal-Weight to Overweight and announces $73 price target.
JP Morgan Upgrades ServiceNow to Overweight
JP Morgan analyst Mark Murphy upgrades ServiceNow (NYSE:NOW) from Neutral to Overweight.